-
Je něco špatně v tomto záznamu ?
Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming
A. D'Alessandro, KC. El Kasmi, L. Plecitá-Hlavatá, P. Ježek, M. Li, H. Zhang, SA. Gupte, KR. Stenmark,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
PubMed
28637353
DOI
10.1089/ars.2017.7217
Knihovny.cz E-zdroje
- MeSH
- energetický metabolismus MeSH
- epigeneze genetická MeSH
- glukosa-6-fosfátdehydrogenasa metabolismus MeSH
- glukosa metabolismus MeSH
- glykolýza MeSH
- hypoxie metabolismus MeSH
- izoenzymy metabolismus MeSH
- koncentrace vodíkových iontů MeSH
- lidé MeSH
- makrofágy MeSH
- mitochondrie metabolismus MeSH
- oxidace-redukce MeSH
- pentózofosfátový cyklus MeSH
- plicní hypertenze etiologie metabolismus MeSH
- regulace genové exprese MeSH
- superoxidy metabolismus MeSH
- uhlík metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
SIGNIFICANCE: The molecular events that promote the development of pulmonary hypertension (PH) are complex and incompletely understood. The complex interplay between the pulmonary vasculature and its immediate microenvironment involving cells of immune system (i.e., macrophages) promotes a persistent inflammatory state, pathological angiogenesis, and fibrosis that are driven by metabolic reprogramming of mesenchymal and immune cells. Recent Advancements: Consistent with previous findings in the field of cancer metabolism, increased glycolytic rates, incomplete glucose and glutamine oxidation to support anabolism and anaplerosis, altered lipid synthesis/oxidation ratios, increased one-carbon metabolism, and activation of the pentose phosphate pathway to support nucleoside synthesis are but some of the key metabolic signatures of vascular cells in PH. In addition, metabolic reprogramming of macrophages is observed in PH and is characterized by distinct features, such as the induction of specific activation or polarization states that enable their participation in the vascular remodeling process. CRITICAL ISSUES: Accumulation of reducing equivalents, such as NAD(P)H in PH cells, also contributes to their altered phenotype both directly and indirectly by regulating the activity of the transcriptional co-repressor C-terminal-binding protein 1 to control the proliferative/inflammatory gene expression in resident and immune cells. Further, similar to the role of anomalous metabolism in mitochondria in cancer, in PH short-term hypoxia-dependent and long-term hypoxia-independent alterations of mitochondrial activity, in the absence of genetic mutation of key mitochondrial enzymes, have been observed and explored as potential therapeutic targets. FUTURE DIRECTIONS: For the foreseeable future, short- and long-term metabolic reprogramming will become a candidate druggable target in the treatment of PH. Antioxid. Redox Signal. 28, 230-250.
Department of Biochemistry and Molecular Genetics University of Colorado Denver Colorado
Department of Pharmacology School of Medicine New York Medical College Valhalla New York
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033857
- 003
- CZ-PrNML
- 005
- 20181022121455.0
- 007
- ta
- 008
- 181008s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1089/ars.2017.7217 $2 doi
- 035 __
- $a (PubMed)28637353
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a D'Alessandro, Angelo $u 1 Department of Biochemistry and Molecular Genetics, University of Colorado - Denver , Colorado.
- 245 10
- $a Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming / $c A. D'Alessandro, KC. El Kasmi, L. Plecitá-Hlavatá, P. Ježek, M. Li, H. Zhang, SA. Gupte, KR. Stenmark,
- 520 9_
- $a SIGNIFICANCE: The molecular events that promote the development of pulmonary hypertension (PH) are complex and incompletely understood. The complex interplay between the pulmonary vasculature and its immediate microenvironment involving cells of immune system (i.e., macrophages) promotes a persistent inflammatory state, pathological angiogenesis, and fibrosis that are driven by metabolic reprogramming of mesenchymal and immune cells. Recent Advancements: Consistent with previous findings in the field of cancer metabolism, increased glycolytic rates, incomplete glucose and glutamine oxidation to support anabolism and anaplerosis, altered lipid synthesis/oxidation ratios, increased one-carbon metabolism, and activation of the pentose phosphate pathway to support nucleoside synthesis are but some of the key metabolic signatures of vascular cells in PH. In addition, metabolic reprogramming of macrophages is observed in PH and is characterized by distinct features, such as the induction of specific activation or polarization states that enable their participation in the vascular remodeling process. CRITICAL ISSUES: Accumulation of reducing equivalents, such as NAD(P)H in PH cells, also contributes to their altered phenotype both directly and indirectly by regulating the activity of the transcriptional co-repressor C-terminal-binding protein 1 to control the proliferative/inflammatory gene expression in resident and immune cells. Further, similar to the role of anomalous metabolism in mitochondria in cancer, in PH short-term hypoxia-dependent and long-term hypoxia-independent alterations of mitochondrial activity, in the absence of genetic mutation of key mitochondrial enzymes, have been observed and explored as potential therapeutic targets. FUTURE DIRECTIONS: For the foreseeable future, short- and long-term metabolic reprogramming will become a candidate druggable target in the treatment of PH. Antioxid. Redox Signal. 28, 230-250.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a uhlík $x metabolismus $7 D002244
- 650 _2
- $a energetický metabolismus $7 D004734
- 650 _2
- $a epigeneze genetická $7 D044127
- 650 _2
- $a regulace genové exprese $7 D005786
- 650 _2
- $a glukosa $x metabolismus $7 D005947
- 650 _2
- $a glukosa-6-fosfátdehydrogenasa $x metabolismus $7 D005954
- 650 _2
- $a glykolýza $7 D006019
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a plicní hypertenze $x etiologie $x metabolismus $7 D006976
- 650 _2
- $a hypoxie $x metabolismus $7 D000860
- 650 _2
- $a izoenzymy $x metabolismus $7 D007527
- 650 _2
- $a makrofágy $7 D008264
- 650 _2
- $a mitochondrie $x metabolismus $7 D008928
- 650 _2
- $a oxidace-redukce $7 D010084
- 650 _2
- $a pentózofosfátový cyklus $7 D010427
- 650 _2
- $a superoxidy $x metabolismus $7 D013481
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a El Kasmi, Karim C $u 2 Developmental Lung Biology and Cardiovascular Pulmonary Research Laboratories, University of Colorado - Denver , Colorado. 3 Department of Pediatric Gastroenterology, University of Colorado - Denver , Colorado.
- 700 1_
- $a Plecitá-Hlavatá, Lydie $u 4 Department of Mitochondrial Physiology, Institute of Physiology , Czech Academy of Sciences, Prague, Czech Republic .
- 700 1_
- $a Ježek, Petr $u 4 Department of Mitochondrial Physiology, Institute of Physiology , Czech Academy of Sciences, Prague, Czech Republic .
- 700 1_
- $a Li, Min $u 2 Developmental Lung Biology and Cardiovascular Pulmonary Research Laboratories, University of Colorado - Denver , Colorado.
- 700 1_
- $a Zhang, Hui $u 2 Developmental Lung Biology and Cardiovascular Pulmonary Research Laboratories, University of Colorado - Denver , Colorado.
- 700 1_
- $a Gupte, Sachin A $u 5 Department of Pharmacology, School of Medicine, New York Medical College , Valhalla, New York.
- 700 1_
- $a Stenmark, Kurt R $u 2 Developmental Lung Biology and Cardiovascular Pulmonary Research Laboratories, University of Colorado - Denver , Colorado.
- 773 0_
- $w MED00006026 $t Antioxidants & redox signaling $x 1557-7716 $g Roč. 28, č. 3 (2018), s. 230-250
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28637353 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181022122000 $b ABA008
- 999 __
- $a ok $b bmc $g 1339624 $s 1030851
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 28 $c 3 $d 230-250 $e 20170814 $i 1557-7716 $m Antioxidants & redox signaling $n Antioxid Redox Signal $x MED00006026
- LZP __
- $a Pubmed-20181008